<DOC>
	<DOCNO>NCT00117104</DOCNO>
	<brief_summary>The purpose study assess Aranesp® dose administer intravenously ( IV ) weekly maintain hemoglobin ( Hgb ) level hemodialysis subject either recombinant human erythropoietin ( rHuEPO ) naïve subject convert rHuEPO therapy administer IV thrice weekly ( TIW ) .</brief_summary>
	<brief_title>Evaluating Aranesp® Subjects With End Stage Renal Disease onChronic Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects end stage renal disease ( ESRD ) hemodialysis Known hypersensitivity Aranesp® ( darbepoetin alfa ) excipients Participating investigational drug device trial Patient available followup assessment Patient disorder compromise ability patient give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>End Stage Renal Disease ( ESRD )</keyword>
	<keyword>Kidney Disease , Dialysis</keyword>
	<keyword>Aranesp® , rHuEPO</keyword>
	<keyword>Anemia , Hemoglobin</keyword>
	<keyword>Dosing , Amgen</keyword>
</DOC>